Last updated on November 2018

A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis


Brief description of study

The study will investigate the efficacy and safety of an oral dose of AJM300 960 milligram (mg)/dose administered three times daily for 8 weeks in participants with active ulcerative colitis.

Clinical Study Identifier: NCT03531892

Contact Investigators or Research Sites near you

Start Over

Public Relations Group

AJM300/CT3 trial site 53
Kurume, Japan
  Connect »